



## INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

<b>(51) International Patent Classification <sup>6</sup> :</b> <b>A61K 38/00, 39/00, 39/395, C07K 14/00, 14/435, 14/705, 16/00, 16/18, 16/46</b>	<b>A1</b>	<b>(11) International Publication Number:</b> <b>WO 95/17202</b> <b>(43) International Publication Date:</b> 29 June 1995 (29.06.95)
<b>(21) International Application Number:</b> PCT/US94/14767 <b>(22) International Filing Date:</b> 21 December 1994 (21.12.94)  <b>(30) Priority Data:</b> 08/172,664 23 December 1993 (23.12.93) US  <b>(71) Applicant:</b> IMMUNEX CORPORATION [US/US]; 51 University Street, Seattle, WA 98101 (US).  <b>(72) Inventors:</b> ARMITAGE, Richard, J.; 5133 Eagle Harbor Drive, Bainbridge Island, WA 98110 (US). FANSLOW, William, C., III; 218 S.W. 327th Place, Federal Way, WA 98023 (US). LONGO, Dan, L.; 9610 Barroll Lane, Kensington, MD 20895 (US). MURPHY, William, J.; 7996 Schooner Court, Frederick, MD 21701 (US).  <b>(74) Agent:</b> PERKINS, Patricia, Anne; Immunex Corporation, 51 University Street, Seattle, WA 98101 (US).		<b>(81) Designated States:</b> AU, CA, FI, JP, NO, NZ, European patent (AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE).  <b>Published</b> <i>With international search report.</i>
<b>(54) Title:</b> METHOD OF PREVENTING OR TREATING DISEASE CHARACTERIZED BY NEOPLASTIC CELLS EXPRESSING CD40  <b>(57) Abstract</b>  There is disclosed a method of treating a mammal afflicted with a disease characterized by neoplastic cells that express CD40, comprising administering a therapeutically effective amount of a CD40 binding protein in a pharmaceutically acceptable buffer. CD40 binding proteins include monoclonal antibodies to CD40, and CD40 ligand. CD40 binding proteins may also be used to prevent disease characterized by neoplastic cells that express CD40, in individuals at risk for such disease.		

**FOR THE PURPOSES OF INFORMATION ONLY**

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AT	Austria	GB	United Kingdom	MR	Mauritania
AU	Australia	GE	Georgia	MW	Malawi
BB	Barbados	GN	Guinea	NE	Niger
BE	Belgium	GR	Greece	NL	Netherlands
BF	Burkina Faso	HU	Hungary	NO	Norway
BG	Bulgaria	IE	Ireland	NZ	New Zealand
BJ	Benin	IT	Italy	PL	Poland
BR	Brazil	JP	Japan	PT	Portugal
BY	Belarus	KE	Kenya	RO	Romania
CA	Canada	KG	Kyrgyzstan	RU	Russian Federation
CF	Central African Republic	KP	Democratic People's Republic of Korea	SD	Sudan
CG	Congo	KR	Republic of Korea	SE	Sweden
CH	Switzerland	KZ	Kazakhstan	SI	Slovenia
CI	Côte d'Ivoire	LI	Liechtenstein	SK	Slovakia
CM	Cameroon	LK	Sri Lanka	SN	Senegal
CN	China	LU	Luxembourg	TD	Chad
CS	Czechoslovakia	LV	Latvia	TG	Togo
CZ	Czech Republic	MC	Monaco	TJ	Tajikistan
DE	Germany	MD	Republic of Moldova	TT	Trinidad and Tobago
DK	Denmark	MG	Madagascar	UA	Ukraine
ES	Spain	ML	Mali	US	United States of America
FI	Finland	MN	Mongolia	UZ	Uzbekistan
FR	France			VN	Viet Nam
GA	Gabon				

## TITLE

5 METHOD OF PREVENTING OR TREATING DISEASE  
CHARACTERIZED BY NEOPLASTIC CELLS EXPRESSING CD40

## TECHNICAL FIELD OF THE INVENTION

The present invention relates to methods of preventing or treating diseases characterized by neoplastic cells expressing CD40. More specifically, the present invention  
10 relates to methods of treating or preventing B-cell lymphomas.

## BACKGROUND OF THE INVENTION

Immunoblastic B-cell lymphomas frequently arise in immunocompromised individuals such as allograft recipients and others receiving long-term immunosuppressive  
15 therapy, AIDS patients and patients with primary immunodeficiency syndromes such as X-linked lymphoproliferative syndrome or Wiscott-Aldrich syndrome (Thomas et al., *Adv. Cancer Res.* 57:329, 1991; Straus et al., *Ann. Intern. Med.* 118:45, 1993). These tumors appear to arise as a result of impaired T cell control of latent Epstein-Barr virus (EBV) infection. Similar lymphomas of human origin can be induced in mice with severe  
20 combined immunodeficiency syndrome (SCID) by inoculation of peripheral blood lymphocytes (PBL) from healthy, EBV-positive individuals (Mosier et al., *Nature* 335:256, 1988; Rowe et al., *J. Exp. Med.* 173:147, 1991).

CD40, a cell-surface antigen present on the surface of both normal and neoplastic human B cells, is a peptide of 277 amino acids having a predicted molecular weight of  
25 30,600, with a 19 amino acid secretory signal peptide comprising predominantly hydrophobic amino acids. This cell surface antigen has been shown to play an important role in B-cell proliferation and differentiation. A cDNA encoding CD40 was isolated from a cDNA library prepared from Burkitt lymphoma cell line Raji (Stamenkovic et al., *EMBO J.* 8:1403, 1989). CD40 is also expressed on the surface of monocytic and epithelial cells,  
30 and on some epithelial carcinomas (E.A. Clark, *Tissue Antigens* 36:33, 1990).

Activated CD4+ T cells express high levels of a ligand for CD40 (CD40L). Human CD40L, a membrane-bound glycoprotein, has recently been cloned from peripheral blood T-cells as described in Spriggs et al., *J. Exp. Med.* 176:1543 (1992), and in United States  
35 Patent Application number 07/969,703, filed October 23, 1992, the disclosure of which is incorporated by reference herein. The cloning of murine CD40L is described in Armitage et al., *Nature* 357:80, 1992. CD40L induces B-cell proliferation in the absence of any co-stimulus, and can also induce production of immunoglobulins in the presence of cytokines.

Monoclonal antibodies to CD40 are known in the art (see, for example, the sections dedicated to B cell antigens in LEUKOCYTE TYPING III; A.J. McMichael ed. Oxford

University Press Oxford, and LEUKOCYTE TYPING IV: Oxford University Press. Oxford). Antibodies to CD40 have been demonstrated to exert costimulatory signals on normal B cells, resulting in proliferative and differentiation responses. Similarly, CD40-L exerts protein stimulatory or costimulatory signals to normal B cells.

5           It has been observed that cross-linking of surface IgM on some B cell lymphoma lines exerts inhibitory signals to the lymphoma cells (Beckwith et al., *J. Immunol.* 147:2411, 1991). Similarly, exposure of malignant B or T cells to stimuli that lead to activation of normal lymphocytes can result in growth arrest of the cells (Ashwell et al., *Science* 237:61, 1987; Bridges et al., *J. Immunol.* 139:4242, 1987; Mercep et al., *J.*  
10 *Immunol.* 140:324, 1988; Sussman et al., *J. Immunol.* 140:2520, 1988; Warner and Scott, *Cell. Immunol.* 115:195, 1988; Page and DeFranco, *J. Immunol.* 140:3717, 1988).

Garnier et al. observed that antibodies to CD40 or another B cell marker, CD23, showed some degree of effectiveness at inhibiting lymphoma formation in SCID mice that had been injected with human PBL and then infected with EBV (Abstract 167, XIVth Intl.  
15 Congress of the Transplantation Society, 1992). However, it was unknown in the art whether the mechanism of action involved was inhibition of binding of CD40L to CD40 by the anti-CD40 antibody, or by some other means. Therefore, there is a need in the art to determine the effects of other anti-CD40 antibodies, and of CD40-L itself, upon B cell lymphomas and other malignant cells that express CD40.

20

### **SUMMARY OF THE INVENTION**

The present invention relates to a method of treating a mammal afflicted with a disease characterized by neoplastic cells that express CD40, comprising administering a therapeutically effective amount of a CD40 binding protein in a pharmaceutically acceptable  
25 buffer. The therapeutically effective amount is from about 0.01 to about 1 mg/kg body weight. CD40 binding proteins may be selected from the group consisting of monoclonal antibodies to CD40, CD40 ligand, and combinations thereof. Particularly preferred monoclonal antibodies are hCD40m2 (deposited at the American Type Culture Collection, Rockville, MD, USA, under the terms of the Budapest Treaty, and given ATCC accession  
30 number HB11459) and hCD40m3, which are described in U.S.S.N. 08/130, 541, filed October 1, 1993. Oligomeric forms of CD40 ligand are particularly preferred, and include a soluble CD40 ligand-Fc fusion protein, and an oligomeric CD40 leucine zipper fusion protein, both of which have been described in U.S.S.N. 07/969,703, filed October 23, 1992. The present invention also relates to a method of preventing a disease characterized  
35 by neoplastic cells that express CD40, in a mammal susceptible to the disease, comprising administering a therapeutically effective amount of a CD40 binding protein in a pharmaceutically acceptable buffer, wherein the therapeutically effective amount is from

about 0.01 to about 1 mg/kg body weight. Neoplastic cells that express CD40 include B lymphoma cells, some melanoma cells and some carcinoma cells.

### **BRIEF DESCRIPTION OF THE DRAWINGS**

5           Figure 1 illustrates the expression of CD40 by several lymphoma cell lines, using anti-CD40 monoclonal antibodies M2 and M3.

Figure 2 demonstrates the inhibition of the proliferation of several lymphoma cell lines by antibodies to CD40 (closed squares); in contrast, mIgG did not inhibit proliferation (open squares).

10           Figure 3 presents a comparison of the effects of soluble anti-CD40 (panel A) or immobilized anti-CD40 (panel B) on lymphoma growth.

Figure 4 demonstrates the ability of soluble CD40 ligand to inhibit the growth of B-cell lymphomas *in vitro*.

15           Figure 5 shows that antibodies to CD40 inhibit the growth of human melanoma cells *in vitro*.

Figure 6 demonstrates the ability of soluble CD40 ligand to inhibit the growth of B-cell lymphomas *in vivo*.

### **DETAILED DESCRIPTION OF THE INVENTION**

20           The present invention relates to methods of treating or preventing diseases characterized by neoplastic cells that express a cell surface molecule known as CD40. The inventive methods utilize a protein (or proteins) that specifically bind CD40 (referred to as a CD40 binding protein) in a non-covalent interaction based upon the proper conformation of the CD40 binding protein and CD40 itself. For example, a CD40 binding protein can  
25           comprise an extracellular region of a CD40 ligand. In other cases, a CD40 binding protein can comprise an antibody that binds CD40 through an antigen binding region. Additional CD40 binding proteins can be prepared through recombinant methods, by preparation of fusion proteins comprising a CD40 binding region (or domain) from a CD40 ligand, or an antibody to CD40, with a second protein, for example, a human immunoglobulin Fc  
30           domain.

#### **CD40**

Human CD40 antigen (CD40) is a peptide of 277 amino acids having a molecular weight of 30,600, and a 19 amino acid secretory signal peptide comprising predominantly  
35           hydrophobic amino acids (Stamenkovic et al., *supra*). A cDNA encoding human CD40 was isolated from a cDNA library prepared from Burkitt lymphoma cell line Raji. The putative protein encoded by the CD40 cDNA contains a putative leader sequence, trans-membrane domain and a number of other features common to membrane-bound receptor

proteins. CD40 has been found to be expressed on B lymphocytes, epithelial cells and some carcinoma cell lines.

CD40 is a member of the tumor necrosis factor (TNF)/nerve growth factor (NGF) receptor family, which is defined by the presence of cysteine-rich motifs in the extracellular region (Smith et al., *Science* 248:1019, 1990; Mallett and Barclay, *Immunology Today* 12:220; 1991). This family includes the lymphocyte antigen CD27, CD30 (an antigen found on Hodgkin's lymphoma and Reed-Sternberg cells), two receptors for TNF, a murine protein referred to as 4-1BB, rat OX40 antigen, NGF receptor, and *Fas* antigen.

CD40 may be detected on the surface of a cell by any one of several means known in the art. For example, an antibody specific for CD40 may be used in a fluorescence-activated cell sorting technique to determine whether cells express CD40, as described in Example 1 herein. Other methods of detecting cell surface molecules are also useful in detecting CD40.

#### 15 CD40 Monoclonal Antibodies

Monoclonal antibodies directed against the CD40 surface antigen (CD40 mAb) have been shown to mediate various biological activities on human B cells. For example, CD40 mAb induce homotypic and heterotypic adhesions (Barrett et al., *J. Immunol.* 146:1722, 1991; Gordon et al., *J. Immunol.* 140:1425, 1988), and increase cell size (Gordon et al., *J. Immunol.* 140:1425, 1988; Valle et al., *Eur. J. Immunol.* 19:1463, 1989). CD40 mAb also induce proliferation of B cells activated with anti-IgM, CD20 mAb, or phorbol ester alone (Clark and Ledbetter, *Proc. Natl. Acad. Sci. USA* 83:4494, 1986; Gordon et al., LEUKOCYTE TYPING III; A.J. McMichael ed. Oxford University Press. Oxford, p. 426; Paulie et al., *J. Immunol.* 142:590, 1989) or in concert with IL-4 (Valle et al., *Eur. J. Immunol.* 19:1463, 1989; Gordon et al., *Eur. J. Immunol.* 17:1535, 1987), and produce IgE (Jabara et al., *J. Exp. Med.* 172:1861, 1990; Gascan et al., *J. Immunol.* 147:8, 1991), IgG, and IgM (Gascan et al., *J. Immunol.* 147:8, 1991) from IL-4-stimulated T cell-depleted cultures.

In addition, CD40 mAb have been reported to enhance IL-4-mediated soluble CD23/FcεRII release from B cells (Gordon and Guy, *Immunol. Today* 8:339, 1987; Cairns et al., *Eur. J. Immunol.* 18:349, 1988) and to promote B cell production of IL-6 (Clark and Shu, *J. Immunol.* 145:1400, 1990). Recently, in the presence of CD<sub>w</sub>32+ adherent cells, human B cell lines have been generated from primary B cell populations with IL-4 and CD40 mAb (Banchereau et al., *Science* 241:70, 1991). Furthermore, germinal center centrocytes can be prevented from undergoing apoptosis if they are activated through CD40 and/or receptors for antigen (Liu et al., *Nature* 342:929, 1989). Each of the above publications describes CD40 mAb that stimulate a biological activity of B cells.

U.S.S.N. 08/130, 541, filed October 1, 1993, the relevant disclosure of which is incorporated by reference, discloses two monoclonal antibodies to CD40, referred to as hCD40m2 and hCD40m3. Unlike other CD40 mAb, hCD40m2 (ATCC HB11459) and hCD40m3 bind CD40 and inhibit binding of CD40 to cells that constitutively express CD40L. Greater than 95% inhibition of binding was observed with hCD40m2 or with CD40 mAb M3, at concentrations as low as 12.5µg/ml, as compared to irrelevant IgG or a control CD40 mAb, G28.5. hCD40m2 was also able to inhibit CD40L-induced TNF-α production.

Additional CD40 monoclonal antibodies may be generated using conventional techniques (*see* U.S. Patent Nos. RE 32,011, 4,902,614, 4,543,439, and 4,411,993 which are incorporated herein by reference; *see also Monoclonal Antibodies, Hybridomas: A New Dimension in Biological Analyses*, Plenum Press, Kennett, McKearn, and Bechtol (eds.), 1980, and *Antibodies: A Laboratory Manual*, Harlow and Lane (eds.), Cold Spring Harbor Laboratory Press, 1988, which are also incorporated herein by reference).

Briefly, an animal is injected with a form of CD40 suitable for generating an immune response against CD40. The animal may be reimmunized as needed until levels of serum antibody to CD40 have reached a plateau, then be given a final boost of soluble CD40, and three to four days later sacrificed. Organs which contain large numbers of B cells such as the spleen and lymph nodes are harvested and disrupted into a single cell suspension by passing the organs through a mesh screen or by rupturing the spleen or lymph node membranes which encapsulate the cells.

Alternatively, suitable cells for preparing monoclonal antibodies are obtained through the use of *in vitro* immunization techniques. Briefly, an animal is sacrificed and the spleen and lymph node cells are removed. A single cell suspension is prepared, and the cells are placed into a culture which contains a form of CD40, which is suitable for generating an immune response as described above. Subsequently, the lymphocytes are harvested and fused as described below.

Cells which are obtained through the use of *in vitro* immunization or from an immunized animal as described above may be immortalized by transfection with a virus such as the Epstein bar virus (EBV) (*see* Glasky and Reading, *Hybridoma* 8(4):377-389, 1989). Alternatively, the harvested spleen and/or lymph node cell suspensions are fused with a suitable myeloma cell in order to create a "hybridoma" which secretes monoclonal antibody. Suitable myeloma lines are preferably defective in the construction or expression of antibodies, and are additionally syngeneic with the cells from the immunized animal. Many such myeloma cell lines are well known in the art and may be obtained from sources such as the American Type Culture Collection (ATCC), Rockville, Maryland (*see Catalogue of Cell Lines & Hybridomas*, 6th ed., ATCC, 1988).

### CD40 Ligand

Activated CD4<sup>+</sup> T cells express high levels of a ligand for CD40 (CD40L). Human CD40L, a membrane-bound glycoprotein, has recently been cloned from peripheral blood T-cells as described in Spriggs et al., *J. Exp. Med.* 176:1543 (1992), and in United States Patent Application number 07/969,703, filed October 23, 1992, the disclosure of which is incorporated by reference herein. The cloning of murine CD40L is described in Armitage et al., *Nature* 357:80, 1992. CD40L induces B-cell proliferation in the absence of any co-stimulus, and can also induce production of immunoglobulins in the presence of cytokines.

CD40-L is a type II membrane polypeptide having an extracellular region at its C-terminus, a transmembrane region and an intracellular region at its N-terminus. Soluble CD40-L comprises an extracellular region of CD40-L (amino acid 47 to amino acid 261 of SEQ ID NO:1) or a fragment thereof. CD40-L biological activity is mediated by binding of the extracellular region of CD40-L with CD40, and includes B cell proliferation and induction of antibody secretion (including IgE secretion).

U.S.S.N. 07/969,703 describes preparation of a soluble CD40-L/Fc fusion protein referred to as CD40-L/FC2. CD40-L/FC2 contains an eight amino acid hydrophilic sequence described by Hopp et al. (Hopp et al., *Bio/Technology* 6:1204,1988; referred to as Flag<sup>®</sup>), an IgG<sub>1</sub> Fc domain, a [Gly<sub>4</sub>Ser]<sub>3</sub> linker sequence (described in U.S. Patent 5,073,627), and the extracellular region of human CD40-L. Also described in U.S.S.N. 07/969,703 is a soluble CD40-L fusion protein referred to as trimeric CD40-L., which contains a 33 amino acid sequence referred to as a "leucine zipper," the eight amino acid hydrophilic sequence described by Hopp et al. (*supra*), followed by the extracellular region of human CD40-L. Both oligomeric forms of CD40-L induce human B cell proliferation in the absence of any co-stimuli, and (in conjunction with the appropriate cytokine) result in the production of IgG, IgE, IgA and IgM.

The CD40-L/FC2 and the trimeric CD40-L described in U.S.S.N. 07/969,703 will be useful in the present inventive methods, as will other forms of CD40-L that can be prepared using known methods of preparing recombinant proteins.

### Additional CD40 Binding Proteins

Binding proteins may also be constructed utilizing recombinant DNA techniques to incorporate the variable regions of a gene which encodes an antibody to CD40. (see James W. Larrick et al., "Polymerase Chain Reaction Using Mixed Primers: Cloning of Human Monoclonal Antibody Variable Region Genes From Single Hybridoma Cells," *Biotechnology* 7:934-938, September 1989; Reichmann et al., "Reshaping Human Antibodies for Therapy," *Nature* 332:323-327, 1988; Roberts et al., "Generation of an Antibody with Enhanced Affinity and Specificity for its Antigen by Protein Engineering," *Nature* 328:731-734, 1987; Verhoeven et al., "Reshaping Human Antibodies: Grafting an



Antilysozyme Activity," *Science* 239:1534-1536, 1988; Chaudhary et al., "A Recombinant Immunotoxin Consisting of Two Antibody Variable Domains Fused to *Pseudomonas* Exotoxin," *Nature* 339:394-397, 1989).

5 Briefly, DNA encoding the antigen-binding site (or CD40 binding domain; variable region) of a CD40 mAb is isolated, amplified, and linked to DNA encoding another protein, for example a human IgG (*see* Verhoeyen et al., *supra*; *see also* Reichmann et al., *supra*). Alternatively, the antigen-binding site (variable region) may be either linked to, or inserted into, another completely different protein (*see* Chaudhary et al., *supra*), resulting in a new protein with antigen-binding sites of the antibody as well as the functional activity  
10 of the completely different protein.

Furthermore, DNA sequences which encode smaller portions of the antibody or variable regions which specifically bind to mammalian CD40 may also be utilized within the context of the present invention. Similarly, the CD40 binding region (extracellular domain) of a CD40 ligand may be used to prepare other CD40 binding proteins. DNA  
15 sequences that encode proteins or peptides that form oligomers will be particularly useful in preparation of CD40 binding proteins comprising an antigen binding domain of CD40 antibody, or an extracellular domain of a CD40 ligand. Certain of such oligomer-forming proteins are disclosed in U.S.S.N. 07/969,703; additional, useful oligomer-forming proteins are also disclosed in U.S.S.N. 08/107,353, filed August 13, 1993, and in  
20 U.S.S.N. 08/145,830, filed September 29, 1993.

Once suitable antibodies or binding proteins have been obtained, they may be isolated or purified by many techniques well known to those of ordinary skill in the art (*see Antibodies: A Laboratory Manual*, Harlow and Lane (eds.), Cold Spring Harbor Laboratory Press, 1988). Suitable techniques include peptide or protein affinity columns,  
25 HPLC or RP-HPLC, purification on protein A or protein G columns, or any combination of these techniques. Recombinant CD40 binding proteins can be prepared according to standard methods, and tested for binding specificity to the CD40 utilizing assays known in the art, including for example ELISA, ABC, or dot blot assays, as well by bioactivity assays such as those described for CD40 mAb.

30

#### SCID mouse models

The term SCID (severe combined immune deficiency) mouse refers to a mutant C.B-17 strain of mouse with a chromosome 16 deficiency that prevents correct T cell receptor and immunoglobulin gene rearrangement, and is thus virtually devoid of functional  
35 B and T cells (Bosma et al., *Nature* 301:257: 1983). SCID mice can be successfully reconstituted with human fetal lymphoid tissues, and with adult human lymphocytes, and have thus been useful as a model for studying human immune function *in vivo* (Mosier et al., *Nature* 335:256, 1988; McKune et al., *Science* 241:1632, 1988; Kamel-Reid and Dick,

5 *Science* 242:1707, 1988). SCID mice reconstituted with human peripheral blood lymphocytes (PBL) from individuals with serological evidence of Epstein-Barr virus (EBV) infection often develop lymphomas of B cell origin (Mosier et al. *supra*; Cannon et al., *J. Clin. Invest.* 85:1333, 1990; Rowe et al., *J. Exp. Med.* 173:147, 1991; Purtilo et al., *Int. J. Cancer* 47:510, 1991). Veronese et al. reported that the presence of functional T cells in the injected PBL was absolutely necessary for progression of latently EBV-infected B cells into tumor masses (*J. Exp. Med.* 176:1763, 1992). The lymphomas that develop in this SCID mouse model are highly aggressive, and analogous to EBV-lymphomas that arise in immunocompromised individuals.

10

#### Administration of CD40 Binding Protein Compositions

The present invention provides therapeutic compositions comprising an effective amount of a CD40 binding protein in a suitable diluent or carrier and methods of treating mammals using the compositions. For therapeutic use, purified CD40 binding protein or a biologically active analog thereof is administered to a patient, preferably a human, for treatment in a manner appropriate to the indication. Thus, for example, CD40 binding protein pharmaceutical compositions (for example, in the form of a soluble extracellular domain of CD40 ligand, or a fragment thereof, or a monoclonal antibody to CD40) which is administered to achieve a desired therapeutic effect can be given by bolus injection, continuous infusion, sustained release from implants, or other suitable technique.

Typically, a CD40 binding protein therapeutic agent will be administered in the form of a pharmaceutical composition comprising purified CD40 binding protein in conjunction with physiologically acceptable carriers, excipients or diluents. Such carriers will be nontoxic to patients at the dosages and concentrations employed. Ordinarily, the preparation of such compositions entails combining a CD40 binding protein with buffers, antioxidants such as ascorbic acid, low molecular weight (less than about 10 residues) polypeptides, proteins, amino acids, carbohydrates including glucose, sucrose or dextrans, chelating agents such as EDTA, glutathione and other stabilizers and excipients. Neutral buffered saline or saline mixed with conspecific serum albumin are exemplary appropriate diluents.

Appropriate dosages may be determined by methods that are known in the art. Typically, therapeutically effective dosages of CD40 binding proteins will be in the range of from about 0.01 to about 1 mg/kg body weight. Moreover, CD40 binding proteins may also be used in conjugates of, or combination with, drugs, toxins or radioactive compounds. Preparation of such conjugates for treatment of various diseases are known in the art (see, for example, Waldmann, *Science* 252:1657, 1991).

Prevention or treatment

These results presented herein indicate that CD40 binding proteins may be of significant clinical use not only in the treatment of B-cell lymphomas, but also in the prevention of EBV-induced B-cell lymphoma that can occur after transplantation or in other instances of immunosuppression, such as AIDS, and which present a significant risk in such patient populations. Since CD40 binding proteins can inhibit various B-cell lymphomas directly, it may not be necessary to use them in conjugates of toxins or radioactive compounds, thereby avoiding toxicity and potential negative effects on normal B cells.

The inventive methods may be useful in prevention of immunoblastic B-cell lymphomas that frequently arise in immunocompromised individuals. In such preventative methods, a mammal at risk of developing an immunoblastic B-cell lymphoma is administered CD40 binding protein. The CD40 binding proteins can be administered for as long as the state of immunocompromise that places the individual at risk exists.

Similarly, the results indicate that the inventive methods may be used to prevent occurrence (or reoccurrence) of neoplastic disease characterized by other types of malignant cells that express CD40 in individuals at risk for such disease. Individuals that are considered at risk in these instances include those with family history or other genetic characteristics indicating predisposition to cancers in which the neoplastic cells express CD40, and individuals that develop drug-resistant neoplastic disease as a result of chemotherapy, in which the drug-resistant neoplastic cells express CD40.

Individuals afflicted with disease characterized by neoplastic cells that express CD40 may also be treated according to the inventive methods. The term treatment, as it is generally understood in the art, refers to initiation of therapy after clinical symptoms or signs of disease have been observed. The inventive methods may be used in conjunction with other therapies appropriate for afflicted individuals, including chemotherapy, radiation therapy, and immunotherapy.

The relevant disclosures of all references cited herein are specifically incorporated by reference. The following examples are intended to illustrate particular embodiments, and not limit the scope, of the invention.

Example 1

This example describes the characterization of human B-cell lymphoma cells and cell lines. Cells used included RL and DB, cell lines obtained from patients with diffuse, large cell lymphomas of B-cell origin (Beckwith et al., supra), and TU2C and CHIM62, EBV-induced lymphomas obtained from SCID mice that had been injected with PBL from EBV-seropositive individuals. These cells were maintained in culture under standard

culture conditions for less than six months prior to initiation of the study. Other cells included Raji, a cell line cultured from a patient with Burkitt's lymphoma, and LCL-2311, a lymphoblastoid cell line generated by infecting human PBL with EBV *in vitro*.

5 All of the cell lines were positive for CD40 expression by flow cytometry, using anti-CD40 monoclonal antibodies M2 and M3; results are shown in Figure 1. RL, DB, and Raji cells were homogeneous in their expression of CD40, whereas the EBV-induced lymphomas from SCID mice were heterogeneous in the staining intensity with anti-CD40. Lymphomas from these mice have previously been demonstrated to be heterogeneous and oligoclonal (Nakamine et al., *Am J. Pathol.* 142:139, 1993), which may account for the  
10 differential expression of CD40. CD20, another B cell marker, was also present on the tumor cells.

### Example 2

This example describes the effect of anti-CD40 antibodies (M2 and M3) on the  
15 proliferative potential of lymphoma cells and cell lines *in vitro*. Proliferation was determined using an assay substantially as described by Rowe et al. (*J. Exp. Med.* 173:147, 1991). Briefly, cell lines were split 24 hours before assays were performed. Cells were resuspended in culture medium to a concentration of  $1 \times 10^5/\text{ml}$ , and 100  $\mu\text{l}$  of cell suspension was plated in 96-well, round bottom microtiter plates (Corning Glass  
20 Works, Corning NY, USA) already containing 100  $\mu\text{l}$  of appropriately diluted reagents (monoclonal anti-CD40 antibodies M2 and M3, obtained from Immunex Corporation, Seattle, WA, USA, or mouse IgG myeloma protein (mIgG) purchased from Cappel, Westchester, PA, USA). Seventy-two hours later, 1  $\mu\text{Ci}$  of [ $^3\text{H}$ ]-thymidine/well (specific activity 6.7 Ci/mmol; New England Nuclear Research Products, Boston, MA, USA) was  
25 added for the final 8 to 18 hours of culture. Cultures were harvested onto glass fiber filters with a PhDCell Harvesting System (Cambridge Technology Inc., Cambridge, MA USA), and [ $^3\text{H}$ ]-thymidine uptake was assayed by liquid scintillation using an LKB  $\beta$ -counter (LKB Instruments Inc., Turku, Finland). Each experiment was performed four to six times, with the results of a representative experiment being presented in Figure 2.

30 Incubation with anti-CD40 monoclonal antibodies M2 and M3 resulted in significant inhibition of the proliferation of RL, DB, LCL-2311 and EBV-lymphoma cell lines tested, with an optimal inhibition of 40-60% occurring at 1-10  $\mu\text{g}/\text{ml}$  of soluble antibody, depending on the lymphoma cell. The Raji cell line did not appear to be significantly affected by soluble anti-CD40.

35 The effects of soluble anti-CD40 on lymphoma growth were then compared to those of immobilized anti-CD40. Briefly, wells were incubated overnight at 37°C with goat anti-mouse antibody. Monoclonal anti-CD40 antibodies M2, M3, an anti-CD20 monoclonal antibody provided by Dr. Kevin Conlon (Laboratory of Experimental

Immunology, BRMP, NCI-FCRDC, Frederick, MD, USA), or mIgG, at a concentration of 10 µg/ml, were then added to the wells, and the wells were incubated for an additional 4 hours at 37°C. The proliferation assays were then performed as described above; results are shown in Figure 3. Immobilization resulted in significantly greater inhibition of proliferation ( $p < 0.05$ ) by the immobilized anti-CD40 antibodies as compared to soluble anti-CD40, or soluble or immobilized anti-CD20. Thus, in contrast to its effects on normal B cells, stimulation of CD40 exerts inhibitory effects on EBV-induced B lymphomas.

10

### Example 3

This example illustrates the effect of CD40 ligand on the growth of B-cell lymphomas *in vitro*. Soluble CD40 ligand (CD40-L; described in U.S.S.N. 07/969,703) was obtained from transfected COS-7 cells as supernatant fluid, and tested in a proliferation assay used as described above, in Example 2, using RL or TU2C cells. Both murine and human CD40-L-containing supernatant fluids were tested, since murine CD40-L binds to human cells that express CD40, and acts as a costimulus in the same manner as human CD40-L. Each lot of supernatant fluid was titrated to determine the concentration that yielded optimal inhibition of proliferation; a 1:5 dilution yielded maximal inhibition.

Exemplary results are presented in Figure 4; values are presented as percent of inhibition compared to control supernatant fluids. The soluble human ligand was inhibitory for the various lymphomas tested, with maximal inhibition seen (50-80%) on RL and TU2C cell lines at a 1:5 dilution of the supernatant fluid. The soluble murine CD40-L produced similar, if not better, inhibitory effects. Control supernatant fluid from COS-7 cells transfected with vector alone actually promoted lymphoma cell growth. Accordingly, the inhibitory effects of CD40-L on B lymphomas parallels that of antibodies to CD40.

25

### Example 4

This example illustrates the effect of anti-CD40 on the growth of human B-cell lymphomas in SCID mice. C.B-17 *scid/scid* (SCID) mice were obtained from the Animal Production Facility (NCI-FCRDC, Frederick, MD, USA) and were not used until 6-8 weeks of age. The mice were kept under specific-pathogen-free conditions at all times; they housed in microisolator cages, and all food, water and bedding were autoclaved before use. Trimethoprim/sulfamethoxazole (40 mg trimethoprim and 200 mg sulfamethoxazole per 320 ml) was included in suspension form in the drinking water given to the mice. All mice received antisera to asialo GM1 (Wako Chemical, Dallas, TX, USA), a marker present on murine NK cells (Murphy et al., *Eur. J. Immunol.* 22:1421; 1992) intravenously one day before cell transfer, to remove host resistance to the tumor.

35

On day 0, SCID mice were injected either intravenously or intraperitoneally with  $5 \times 10^6$  RL or TU2C cells. The tumor cell recipients then received either 2  $\mu$ g of anti-CD40, or mIgG in 0.2 ml HBSS (Hank's balanced salt solution) intravenously every other day for a period of 10 days (total of 5 injections), starting at day 0, 3, or 14. Mice were monitored for tumor development and progression; moribund mice were euthanized. All mice were necropsied for evidence of tumor. Liver, kidney and lymphoid organs were analyzed histologically for presence of tumor cells. Both parametric (student's t test) and non-parametric (Wilcoxon rank sum test) analyses were performed to determine if the groups differed significantly ( $p < 0.05$ ). All experiments had 3-10 mice per group, and were performed 2-3 times. The results are presented in Table 1 below.

Table 1: Effect of anti-CD40 administration on survival in tumor-bearing mice

Experiment	Tumor (Route)	Treatment (Initiation)	No. of Mice	Mean Day of Death
1	RL (i.p.)	None	3	34 $\pm$ 0
	RL (i.p.)	anti-CD40 (day 0)	6	>138 $\pm$ 26.5 <sup>a</sup>
	TU2C (i.p.)	None	3	28 $\pm$ 0
	TU2C (i.p.)	anti-CD40 (day 0)	6	>76 $\pm$ 45.0 <sup>b</sup>
2	TU2C (i.v.)	None	6	30 $\pm$ 6.3
	TU2C (i.v.)	anti-CD40 (day 3)	6	>38 $\pm$ 2.6 <sup>c</sup>
	TU2C (i.v.)	anti-CD40 (day 14)	6	>32 $\pm$ 4.6 <sup>c</sup>
3	RL (i.p.)	None	6	39 $\pm$ 3.5
	RL (i.p.)	anti-CD40 (day 3)	6	>107 $\pm$ 21.9 <sup>a</sup>
	RL (i.p.)	anti-CD40 (day 14)	6	>79 $\pm$ 34.3 <sup>d</sup>

a: No deaths due to tumor; all (6) mice surviving

b: Two deaths due to tumor, other (4 out of 6 mice) showing no evidence of tumor.

c: One of six recipient mice showing no evidence of disease.

d: Three deaths due to tumor; three mice surviving.

Anti-CD40 significantly ( $p < 0.05$ ) improved survival of mice receiving either RL or TU2C tumors when treatment was initiated on day 0, 3 or 14. When SCID mice were treated with anti-CD40 on day 0, no evidence of tumor was present in the mice receiving the RL B-cell lymphoma line after several months. However, some mice receiving the EBV lymphoma TU2C and anti-CD40 did develop tumor several weeks after cessation of anti-CD40 treatment.

Differential patterns of metastatic growth were observed for the different routes of tumor cell administration. Mice receiving the EBV-induced lymphomas i.p. developed peritoneal tumors with extensive metastases in the lymph nodes and liver, whereas mice receiving the lymphomas i.v. primarily developed renal metastases. Anti-CD40 was capable of significantly inhibiting tumor growth and promoting survival of recipient mice regardless of the route of tumor administration.

Treatment of tumor-bearing mice with anti-CD40 also resulted in significantly improved survival when treatment was initiated 3 or 4 days after tumor cell transfer, and even as late as 14 days. These results indicate that anti-CD40 treatment was also efficacious when treatment was initiated with relatively large and extensive tumor burdens ( $>1 \text{ cm}^3$ ) in the recipient mice.

### Example 5

This example illustrates the effect of anti-CD40 on the growth of tumors in SCID mice injected with PBL from EBV-seropositive individuals. SCID mice (described in Example 4 above) were given injections of recombinant human growth hormone (rhGH: Genentech, South San Francisco, CA, USA), which has been demonstrated to promote EBV-lymphogenesis in huPBL-SCID mice (Murphy et al., *Brain Behav. Immun.* 6:355; 1992), presumable due to promotion of human T-cell engraftment in treated mice (Murphy et al., *Proc. Natl. Acad. Sci. USA* 89:4481; 1992). T-cell engraftment appears to be essential for human B-cell lymphoma formation in the huPBL-SCID model (18). rhGH (10  $\mu\text{g}$  in 0.2 ml HBSS) was given i.p. on day 0 and every other day until time of assay 4-8 weeks later. Human PBLs were obtained from healthy donors in leukopacks. Anti-asialo GM-1 was administered as described for Example 4.

Human PBL were obtained from healthy, EBV-seropositive donors in leukopacks. All donors were screened for antibodies to human immunodeficiency virus type 1 (HIV-1) and for hepatitis B surface antigen (HBsAg), and provided informed consent before donation. The PBL were purified by counter-current elutriation, and the lymphocyte fraction, containing  $>90\%$  lymphocytes as assessed by flow cytometry, were obtained. The PBL ( $1 \times 10^8$ ) were injected i.p. into recipient SCID mice on day 0.

Mice were treated with anti-CD40, anti-CD20, or with mIgG (2  $\mu\text{g}$ /0.2 ml PBS) i.p. every other day for 20 days for a total of 10 injections. Table 2 presents results representative of three experiments with 5-8 mice per group.

Table 2: Effect of anti-CD40 administration of EBV-induced B-cell lymphoma development in huPBL-SCID mice chimeras

Experiment	Treatment	No. of Mice	Mean Day of Death	% Incidence of Lymphoma <sup>a</sup>
A	msIgG	6	31.4±3.9	100%
	anti-CD40	6	>50 <sup>b</sup>	0%
B	msIgG	8	26.3±2.1 <sup>c</sup>	87%
	anti-CD40	8	>55 <sup>b</sup>	0%
C	msIgG	5	33.2±1.2	100%
	anti-CD40	5	>53 <sup>b</sup>	0%
	anti-CD20	5	>53	0%

a: Mice were moribund with evidence of extensive tumor nodules in the peritoneal cavity and evidence of lymphoma by histological assessment.

b: Treatment with anti-CD40 resulted in no deaths due to lymphoma and no evidence of lymphoma when assayed 2-6 weeks after cessation of anti-CD40 treatment. Anti-CD40 or anti-CD20 significantly ( $p<0.001$ ) increased survival compared to control recipients.

c: One out of 8 mice surviving and showing no evidence of tumor.

The results demonstrated that treatment of huPBL-SCID chimeric mice with anti-CD40 at the time of huPBL transfer completely prevented the development of human B-cell lymphomas in the mice. Although anti-CD20 had no effect on the lymphomas *in vitro*, treatment of the huPBL-SCID chimeras with anti-CD20 also prevented the occurrence of lymphoma.

#### Example 6

This example illustrates the effect of anti-CD40 on the engraftment of human T (HLA<sup>+</sup>, CD3<sup>+</sup>) and B (HLA<sup>+</sup>, CD3<sup>-</sup>) cells in SCID mice. huPBL-SCID mice chimeras were prepared as described in Example 5 above. Percentages of human T and B cells found in the peritoneal cavity were determined, and the human immunoglobulin in the serum quantitated by enzyme-linked immunosorbent assay (ELISA). Animals were also examined for the presence of lymphoma; those animal that evidenced lymphoma were moribund, with evidence of extensive tumor nodules in the peritoneal cavity. Mice were assayed 4-8 weeks after huPBL transfer, with all control (msIg) treated mice succumbing to EBV-induced B cell lymphoma at day 33.2±1.2.

Single cell suspensions of peritoneal cavity cells were obtained, and evaluated by flow cytometry (FACS). Staining was performed in the presence of 2% human AB serum (Gibco BRL, Grand Island, NY, USA) to saturate human and mouse Fc receptors. Reagents used in the FACS analysis were monoclonal anti human-HLA-ABC conjugated to fluorescein isothiocyanate (FITC; Olympus, Lake Success, NY, USA), and Leu4-biotinylated anti-CD3 (Becton-Dickinson, Mountain View, CA, USA). After primary antibody incubation, cells were analyzed using an EPICS flow cytometer.



- Human immunoglobulin levels were assayed by ELISA. Flat-bottom 96-well microtiter plates (Corning Glass Works, Corning, NY, USA) were coated with goat anti-human Ig (Kirkegaard and Perry Laboratory, Gaithersburg, MD, USA) at 1 µg/ml in PBS, washed twice and blocked with 5% goat serum. The wells were then incubated with sera obtained from the huPBL-SCID mice chimeras, or a titration of human IgM+IgG standard (DAKO Corp., Santa Barbara, CA, USA). After washing four times, alkaline phosphatase-conjugated goat anti-human Ig (Kirkegaard and Perry Laboratory, Gaithersburg, MD, USA) was added. The plates were incubated, and washed again. After the final wash, substrate was added, and the enzyme reaction allowed to develop. OD was measured at 402 nm. Results are presented in Table 3.

Table 3: Effect of anti-CD40 on human B-cell engraftment and EBV-induced development in huPBL-SCID chimera mice

Experiment	Animal No.	Treatment	# Peritoneal Cells (x 10 <sup>6</sup> )	% cells HLA <sup>+</sup> , CD3 <sup>-</sup>	% cells HLA <sup>+</sup> , CD3 <sup>+</sup>	Human serum Ig (µg/ml)	Presence of Lymphoma
A	1	msIgG	1.6	1.8	10.3	90	+
	2	msIgG	1.4	0.8	2.8	120	+
	3	msIgG	1.1	0.6	0.4	155	+
	4	msIgG	1.5	0.6	1.4	406	+
	5	msIgG	0.6	2.3	10.7	500	+
	6	anti-CD40	0.8	2.8	6.1	2.7	-
	7	anti-CD40	1.4	1.0	1.1	0.8	-
	8	anti-CD40	1.8	2.7	5.2	2.7	-
	9	anti-CD40	1.4	6.1	10.5	5.0	-
	10	anti-CD40	1.2	2.0	5.2	0.2	-
B	1	anti-CD40	9.0	6.1	7.2	11.7	-
	2	anti-CD40	2.1	0.3	0.9	1.0	-
	3	anti-CD40	1.8	0.5	6.7	15.0	-
	4	anti-CD40	0.6	5.1	5.0	4.0	-
	5	anti-CD40	2.0	0.9	2.4	5.0	-
C	1	anti-CD20	0.8	0.0	8.1	6.5	-
	2	anti-CD20	1.4	0.0	1.1	10.3	-
	3	anti-CD20	1.8	0.0	5.2	4.8	-
	4	anti-CD20	1.4	0.0	0.8	7.9	-
	5	anti-CD40	1.2	10.3	0.0	412.0	-
	6	anti-CD40	9.0	1.5	0.0	86.4	-
	7	anti-CD40	2.1	5.1	22.9	1110.0	-
	8	anti-CD40	1.8	0.6	0.9	18.5	-

Treatment with anti-CD40 did not prevent the engraftment of human T and B cells, as determined by FACS analysis of peritoneal cells, and determination of serum levels of human immunoglobulin. In Experiment A, the extent of human cell engraftment appeared quantitatively less in anti-CD40 treated animals than in animals receiving msIgG, based on the levels of human Ig in the serum. However, since the huPBL-SCID chimeric mice that did not receive anti-CD40 developed B-cell lymphomas, the high levels of human immunoglobulin detected are likely to be due to the B-cell lymphoma. In contrast to anti-CD40, treatment with anti-CD20 appeared to inhibit engraftment of B cells, both as indicated in lower percentages of B cells and in decreased levels of human Ig in the serum.

### Example 7

This example illustrates the effect of anti-CD40 and msIgG on the engraftment of B cells in SCID mice. huPBL-SCID mice chimeras were prepared as described in Example 5 above, except that the PBLs were obtained from EBV-negative donors. The chimeras were thus not expected to develop lymphomas, thereby providing a more accurate indication of engraftment of normal B cells. The chimeras were treated with either anti-CD40 or anti-CD20, and percentages of human T and B cells found in the peritoneal cavity were determined, and the amount of human immunoglobulin in the serum quantitated as described in Example 6. Results are shown in Table 5.

Table 5: Effect of Anti-CD40 Treatment on Human Immunoglobulin Production in huPBL-SCID Chimeras

Animal #	Treatment <sup>a</sup>	Serum Immunoglobulin (µg/ml)
1.	huPBL, msIgG	125.0
2.	huPBL, msIgG	150.0
3.	huPBL, msIgG	1.7
4.	huPBL, msIgG	94.0
5.	huPBL, msIgG	112.0
6.	huPBL, msIgG	18.8
7.	huPBL, anti-CD40	194.0
8.	huPBL, anti-CD40	269.0
9.	huPBL, anti-CD40	239.0
10.	huPBL, anti-CD40	119.0
11.	huPBL, anti-CD40	206.0
12.	huPBL, anti-CD40	150.0

<sup>a</sup>: SCID mice received 100 million huPBL i.p. with 2 µg of anti-CD40 or msIgG given i.p. every other day for 20 days. Mice were analyzed for serum immunoglobulin levels using a human immunoglobulin-specific ELISA 3-4 weeks after huPBL transfer.

Treatment with anti-CD40 did promote engraftment of human B cells, indicating that anti-CD40 has additional value for treatment or prevention of lymphomas due to its ability to remove lymphoma cells while sparing normal B cells.

5

### Example 8

This example illustrates the effect of antibodies to CD40 on the growth of human melanoma cells *in vitro*. Antibody to CD40 ligand (M2) was tested in a proliferation assay substantially as described above, in Example 2, using M16 human melanoma cells, which  
10 express CD40..

The results obtained are presented in Figure 5; values are presented as percent of inhibition compared to control supernatant fluids. Incubation with anti-CD40 monoclonal antibody M2 resulted in significant inhibition of the proliferation of M16 human melanoma cell line tested, with as little as 0.1 ng/ml causing inhibition of almost 50%. Increased  
15 inhibition was observed with increasing concentration of anti-CD40.

### Example 9

This example illustrates the effect of recombinant human CD40 ligand on the growth of human B-cell lymphomas in SCID mice. SCID mice were obtained, and treated  
20 substantially as described in Example 4, above. On day 0, SCID mice were injected either intraperitoneally with  $5 \times 10^6$  RL or TU2C cells. The tumor cell recipients then received 100  $\mu$ l of concentrated supernatant fluid from cells transfected with either a vector encoding human CD40 ligand, or vector alone (control). Two concentrations of the CD40 ligand-containing supernatant fluid were tested: a ten-fold concentrate and a two-fold concentrate  
25 (10x and 2x, respectively). The concentrated supernatants were administered intraperitoneally every third day for a period of 15 days (total of 5 injections), starting at day 3. Mice were monitored for tumor development and progression; moribund mice were euthanized. All mice were necropsied for evidence of tumor. Liver, kidney and lymphoid organs were analyzed histologically for presence of tumor cells. Both parametric (student's  
30 t test) and non-parametric (Wilcoxon rank sum test) analyses were performed to determine if the groups differed significantly ( $p < 0.05$ ). All experiments had 7-10 mice per group, and were performed 3 times.

The results of an exemplary experiment utilizing RL cells are shown in Figure 6. Similar to the results obtained *in vitro* in Example 3, recombinant CD40 ligand inhibited the  
35 growth of tumor cells *in vivo* in SCID mice.

## SEQUENCE LISTING

- (1) GENERAL INFORMATION:
- 5 (i) APPLICANT: ARMITAGE, RICHARD  
FANSLOW, WILLIAM  
LONGO, DAN L.  
MURPHY, WILLIAM
- 10 (ii) TITLE OF INVENTION: METHOD OF PREVENTING OR TREATING  
DISEASE CHARACTERIZED BY NEOPLASTIC CELLS  
EXPRESSING CD40
- 15 (iii) NUMBER OF SEQUENCES: 2
- (iv) CORRESPONDENCE ADDRESS:  
20 (A) ADDRESSEE: IMMUNEX CORPORATION  
(B) STREET: 51 UNIVERSITY STREET  
(C) CITY: SEATTLE  
(D) STATE: WASHINGTON  
(E) COUNTRY: USA  
(F) ZIP: 98101
- 25 (v) COMPUTER READABLE FORM:  
(A) MEDIUM TYPE: Floppy disk  
(B) COMPUTER: Macintosh  
(C) OPERATING SYSTEM: Apple Macintosh System 7.1  
(D) SOFTWARE: Microsoft Word for Macintosh, Version #5.1a
- 30 (vi) CURRENT APPLICATION DATA:  
(A) APPLICATION NUMBER:  
(B) FILING DATE: December 21, 1994  
(C) CLASSIFICATION:
- 35 (vii) PRIOR APPLICATION DATA:  
(A) APPLICATION NUMBER: USSN 08/172,664  
(B) FILING DATE: December 23, 1993  
(C) CLASSIFICATION:
- 40 (viii) ATTORNEY/AGENT INFORMATION:  
(A) NAME: Perkins, Patricia A.  
(B) REGISTRATION NUMBER: 34,693  
(C) REFERENCE/DOCKET NUMBER: 2818
- 45 (ix) TELECOMMUNICATION INFORMATION:  
(A) TELEPHONE: (206)587-0430  
(B) TELEFAX: (206)233-0644
- 50 (2) INFORMATION FOR SEQ ID NO:1:
- 55 (i) SEQUENCE CHARACTERISTICS:  
(A) LENGTH: 840 base pairs  
(B) TYPE: nucleic acid  
(C) STRANDEDNESS: single  
(D) TOPOLOGY: linear
- 60 (ii) MOLECULE TYPE: cDNA
- (iii) HYPOTHETICAL: NO

(iv) ANTI-SENSE: NO

(vi) ORIGINAL SOURCE:  
 5 (A) ORGANISM: Homo sapiens

(vii) IMMEDIATE SOURCE:  
 (B) CLONE: CD40-L

(ix) FEATURE:  
 (A) NAME/KEY: CDS  
 (B) LOCATION: 46..831

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:1:

	TGCCACCTTC TCTGCCAGAA GATACCATT TCAACTTTAAC ACAGC ATG ATC GAA	54
	Met Ile Glu	
	1	
20	ACA TAC AAC CAA ACT TCT CCC CGA TCT GCG GCC ACT GGA CTG CCC ATC	102
	Thr Tyr Asn Gln Thr Ser Pro Arg Ser Ala Ala Thr Gly Leu Pro Ile	
	5 10 15	
25	AGC ATG AAA ATT TTT ATG TAT TTA CTT ACT GTT TTT CTT ATC ACC CAG	150
	Ser Met Lys Ile Phe Met Tyr Leu Leu Thr Val Phe Leu Ile Thr Gln	
	20 25 30 35	
30	ATG ATT GGG TCA GCA CTT TTT GCT GTG TAT CTT CAT AGA AGG TTG GAC	198
	Met Ile Gly Ser Ala Leu Phe Ala Val Tyr Leu His Arg Arg Leu Asp	
	40 45 50	
35	AAG ATA GAA GAT GAA AGG AAT CTT CAT GAA GAT TTT GTA TTC ATG AAA	246
	Lys Ile Glu Asp Glu Arg Asn Leu His Glu Asp Phe Val Phe Met Lys	
	55 60 65	
40	ACG ATA CAG AGA TGC AAC ACA GGA GAA AGA TCC TTA TCC TTA CTG AAC	294
	Thr Ile Gln Arg Cys Asn Thr Gly Glu Arg Ser Leu Ser Leu Leu Asn	
	70 75 80	
45	TGT GAG GAG ATT AAA AGC CAG TTT GAA GGC TTT GTG AAG GAT ATA ATG	342
	Cys Glu Glu Ile Lys Ser Gln Phe Glu Gly Phe Val Lys Asp Ile Met	
	85 90 95	
50	TTA AAC AAA GAG GAG ACG AAG AAA GAA AAC AGC TTT GAA ATG CAA AAA	390
	Leu Asn Lys Glu Glu Thr Lys Lys Glu Asn Ser Phe Glu Met Gln Lys	
	100 105 110 115	
55	GGT GAT CAG AAT CCT CAA ATT GCG GCA CAT GTC ATA AGT GAG GCC AGC	438
	Gly Asp Gln Asn Pro Gln Ile Ala Ala His Val Ile Ser Glu Ala Ser	
	120 125 130	
60	AGT AAA ACA ACA TCT GTG TTA CAG TGG GCT GAA AAA GGA TAC TAC ACC	486
	Ser Lys Thr Thr Ser Val Leu Gln Trp Ala Glu Lys Gly Tyr Tyr Thr	
	135 140 145	
	ATG AGC AAC AAC TTG GTA ACC CTG GAA AAT GGG AAA CAG CTG ACC GTT	534
	Met Ser Asn Asn Leu Val Thr Leu Glu Asn Gly Lys Gln Leu Thr Val	
	150 155 160	

	AAA	AGA	CAA	GGA	CTC	TAT	TAT	ATC	TAT	GCC	CAA	GTC	ACC	TTC	TGT	TCC	582
	Lys	Arg	Gln	Gly	Leu	Tyr	Tyr	Ile	Tyr	Ala	Gln	Val	Thr	Phe	Cys	Ser	
		165					170					175					
5	AAT	CGG	GAA	GCT	TCG	AGT	CAA	GCT	CCA	TTT	ATA	GCC	AGC	CTC	TGC	CTA	630
	Asn	Arg	Glu	Ala	Ser	Ser	Gln	Ala	Pro	Phe	Ile	Ala	Ser	Leu	Cys	Leu	
	180					185					190					195	
10	AAG	TCC	CCC	GGT	AGA	TTC	GAG	AGA	ATC	TTA	CTC	AGA	GCT	GCA	AAT	ACC	678
	Lys	Ser	Pro	Gly	Arg	Phe	Glu	Arg	Ile	Leu	Leu	Arg	Ala	Ala	Asn	Thr	
					200					205					210		
15	CAC	AGT	TCC	GCC	AAA	CCT	TGC	GGG	CAA	CAA	TCC	ATT	CAC	TTG	GGA	GGA	726
	His	Ser	Ser	Ala	Lys	Pro	Cys	Gly	Gln	Gln	Ser	Ile	His	Leu	Gly	Gly	
				215					220					225			
20	GTA	TTT	GAA	TTG	CAA	CCA	GGT	GCT	TCG	GTG	TTT	GTC	AAT	GTG	ACT	GAT	774
	Val	Phe	Glu	Leu	Gln	Pro	Gly	Ala	Ser	Val	Phe	Val	Asn	Val	Thr	Asp	
			230					235					240				
	CCA	AGC	CAA	GTG	AGC	CAT	GGC	ACT	GGC	TTC	ACG	TCC	TTT	GGC	TTA	CTC	822
	Pro	Ser	Gln	Val	Ser	His	Gly	Thr	Gly	Phe	Thr	Ser	Phe	Gly	Leu	Leu	
		245					250					255					
25	AAA	CTC	TGAACAGTGT	CA													840
	Lys	Leu															
	260																
30	(2) INFORMATION FOR SEQ ID NO:2:																
	(i) SEQUENCE CHARACTERISTICS:																
	(A) LENGTH: 261 amino acids																
	(B) TYPE: amino acid																
35	(D) TOPOLOGY: linear																
	(ii) MOLECULE TYPE: protein																
	(xi) SEQUENCE DESCRIPTION: SEQ ID NO:12:																
40	Met	Ile	Glu	Thr	Tyr	Asn	Gln	Thr	Ser	Pro	Arg	Ser	Ala	Ala	Thr	Gly	
	1				5					10					15		
45	Leu	Pro	Ile	Ser	Met	Lys	Ile	Phe	Met	Tyr	Leu	Leu	Thr	Val	Phe	Leu	
				20					25					30			
	Ile	Thr	Gln	Met	Ile	Gly	Ser	Ala	Leu	Phe	Ala	Val	Tyr	Leu	His	Arg	
			35					40					45				
50	Arg	Leu	Asp	Lys	Ile	Glu	Asp	Glu	Arg	Asn	Leu	His	Glu	Asp	Phe	Val	
		50					55					60					
	Phe	Met	Lys	Thr	Ile	Gln	Arg	Cys	Asn	Thr	Gly	Glu	Arg	Ser	Leu	Ser	
	65					70					75					80	
55	Leu	Leu	Asn	Cys	Glu	Glu	Ile	Lys	Ser	Gln	Phe	Glu	Gly	Phe	Val	Lys	
					85					90					95		
60	Asp	Ile	Met	Leu	Asn	Lys	Glu	Glu	Thr	Lys	Lys	Glu	Asn	Ser	Phe	Glu	
				100					105					110			

	Met	Gln	Lys	Gly	Asp	Gln	Asn	Pro	Gln	Ile	Ala	Ala	His	Val	Ile	Ser
			115					120					125			
5	Glu	Ala	Ser	Ser	Lys	Thr	Thr	Ser	Val	Leu	Gln	Trp	Ala	Glu	Lys	Gly
		130					135					140				
	Tyr	Tyr	Thr	Met	Ser	Asn	Asn	Leu	Val	Thr	Leu	Glu	Asn	Gly	Lys	Gln
	145					150					155					160
10	Leu	Thr	Val	Lys	Arg	Gln	Gly	Leu	Tyr	Tyr	Ile	Tyr	Ala	Gln	Val	Thr
					165					170					175	
	Phe	Cys	Ser	Asn	Arg	Glu	Ala	Ser	Ser	Gln	Ala	Pro	Phe	Ile	Ala	Ser
15				180					185					190		
	Leu	Cys	Leu	Lys	Ser	Pro	Gly	Arg	Phe	Glu	Arg	Ile	Leu	Leu	Arg	Ala
			195					200					205			
	Ala	Asn	Thr	His	Ser	Ser	Ala	Lys	Pro	Cys	Gly	Gln	Gln	Ser	Ile	His
20			210				215					220				
	Leu	Gly	Gly	Val	Phe	Glu	Leu	Gln	Pro	Gly	Ala	Ser	Val	Phe	Val	Asn
	225					230					235					240
25	Val	Thr	Asp	Pro	Ser	Gln	Val	Ser	His	Gly	Thr	Gly	Phe	Thr	Ser	Phe
					245					250					255	
	Gly	Leu	Leu	Lys	Leu											
				260												
30																

## CLAIMS

5           What is claimed is:

1. A method of treating a mammal afflicted with a disease characterized by neoplastic cells that express CD40, comprising administering a therapeutically effective amount of a CD40 binding protein in a pharmaceutically acceptable buffer, wherein the  
10 therapeutically effective amount is from about 0.01 to about 1 mg/kg body weight.

2. The method of claim 1, wherein the CD40 binding protein is selected from the group consisting of monoclonal antibodies to CD40, CD40 ligand, and combinations thereof.

15 3. The method of claim 2, wherein the CD40 binding protein is monoclonal antibody hCD40m2 (ATCC HB11459).

4. The method of claim 2, wherein the CD40-binding protein is monoclonal  
20 antibody hCD40m3.

5. The method of claim 2, wherein the CD40-binding protein is soluble, oligomeric CD40 ligand.

25 6. The method of claim 5, wherein the soluble, oligomeric CD40 ligand is an Fc fusion protein.

7. The method of claim 5, wherein the soluble, oligomeric CD40 ligand is a leucine zipper fusion protein.

30 8. The method of claim 1, wherein the cells expressing CD40 are selected from the group consisting of B lymphoma cells, melanoma cells and carcinoma cells.

9. The method of claim 2, wherein the cells expressing CD40 are selected from the  
35 group consisting of B lymphoma cells, melanoma cells and carcinoma cells.

10. The method of claim 3, wherein the cells expressing CD40 are selected from the group consisting of B lymphoma cells, melanoma cells and carcinoma cells.



11. The method of claim 4, wherein the cells expressing CD40 are selected from the group consisting of B lymphoma cells, melanoma cells and carcinoma cells.

5           12. The method of claim 5, wherein the cells expressing CD40 are selected from the group consisting of B lymphoma cells, melanoma cells and carcinoma cells.

13. The method of claim 6, wherein the cells expressing CD40 are selected from the group consisting of B lymphoma cells, melanoma cells and carcinoma cells.

10

14. The method of claim 7, wherein the cells expressing CD40 are selected from the group consisting of B lymphoma cells, melanoma cells and carcinoma cells.

15           15. A method of preventing a disease characterized by neoplastic cells that express CD40, in a mammal susceptible to the disease, comprising administering a therapeutically effective amount of a CD40 binding protein in a pharmaceutically acceptable buffer, wherein the therapeutically effective amount is from about 0.01 to about 1 mg/kg body weight.

20           16. The method of claim 15, wherein the CD40 binding protein is selected from the group consisting of monoclonal antibodies to CD40, CD40 ligand, and combinations thereof.

25           17. The method of claim 16, wherein the CD40 binding protein is monoclonal antibody hCD40m2 (ATCC HB11459).

18. The method of claim 16, wherein the CD40-binding protein is monoclonal antibody hCD40m3.

30           19. The method of claim 16, wherein the CD40-binding protein is soluble, oligomeric CD40 ligand.

20. The method of claim 19, wherein the soluble, oligomeric CD40 ligand is an Fc fusion protein.

35

21. The method of claim 19, wherein the soluble, oligomeric CD40 ligand is a leucine zipper fusion protein.

22. The use of a CD40 binding protein in providing a medication for administration to a mammal afflicted with a disease characterized by neoplastic cells that express CD40.

5           23. The use of claim 22, wherein the CD40 binding protein is selected from the group consisting of monoclonal antibodies to CD40, CD40 ligand, and combinations thereof.

            24. The use of claim 23, wherein the CD40 binding protein is monoclonal antibody  
10   hCD40m2 (ATCC HB11459).

            25. The use of claim 23, wherein the CD40-binding protein is monoclonal antibody hCD40m3.

15           26. The use of claim 23, wherein the CD40-binding protein is soluble, oligomeric CD40 ligand.

            27. A method of preparing a medication for administration to a mammal afflicted with a disease characterized by neoplastic cells that express CD40, comprising formulating  
20   a CD40 binding protein in a suitable excipient or carrier.

            28. The method of claim 27, wherein the CD40 binding protein is selected from the group consisting of monoclonal antibodies to CD40, CD40 ligand, and combinations thereof.

25           29. The method of claim 28, wherein the CD40 binding protein is monoclonal antibody hCD40m2 (ATCC HB11459).

            30. The method of claim 28, wherein the CD40-binding protein is monoclonal  
30   antibody hCD40m3.

            31. The method of claim 28, wherein the CD40-binding protein is soluble, oligomeric CD40 ligand.




FIGURE 1




Figure 2A




Figure 2B




Figure 2C




Figure 2D




Figure 2E




Figure 2F




FIGURE 3B




FIGURE 3A




FIGURE 4





FIGURE 5

Effect of huCD40Ligand on RL-bearing mice



DAY OF DEATH

FIGURE 6



## INTERNATIONAL SEARCH REPORT

International application No.

PCT/US94/14767

**A. CLASSIFICATION OF SUBJECT MATTER**

IPC(6) :Please See Extra Sheet.

US CL :Please See Extra Sheet.

According to International Patent Classification (IPC) or to both national classification and IPC

**B. FIELDS SEARCHED**

Minimum documentation searched (classification system followed by classification symbols)

U.S. : 424/130.1, 133.1, 134.1, 136.1, 138.1, 141.1, 143.1, 144.1.; 435/252.3, 320.1; 514/2, 8; 530/350, 351, 388. 22, 380.73

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practicable, search terms used)

APS, DIALOG, BIOSIS, EMBASE, CHEM ABSTRACTS, MEDLINE, WPI  
SEARCH TERMS: CD40, C40 LIGAND, CANCER, TUMOR, NEOPLASIA**C. DOCUMENTS CONSIDERED TO BE RELEVANT**

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
Y	US, A, 5,247,069 (LEDBETTER ET AL.) 21 SEPTEMBER 1993, SEE ENTIRE DOCUMENT.	1-31
Y	US, A, 5,182,368 (LEDBETTER ET AL.) 26 JUNE 1993, SEE ENTIRE DOCUMENT.	1-31
Y	PERIOD BIOL. VOLUME 92, NUMBER 1, ISSUED 1990, JOVANOVIC ET AL. "THE ROLE OF CD40 IN THE PROLIFERATION OF CLL B LYMPHOCYTES", PAGES 89-90, SEE ENTIRE DOCUMENT.	1-31
Y	KNAPP ET AL., "LEUKOCYTE TYPING IV", PUBLISHED 1989 BY OXFORD UNIVERSITY PRESS, PAGES 90-91, SEE ENTIRE DOCUMENT.	1-31



Further documents are listed in the continuation of Box C.



See patent family annex.

•

Special categories of cited documents:

"T"

later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

"A"

document defining the general state of the art which is not considered to be of particular relevance

"X"

document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

"E"

earlier document published on or after the international filing date

"L"

document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)

"Y"

document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art

"O"

document referring to an oral disclosure, use, exhibition or other means

"P"

document published prior to the international filing date but later than the priority date claimed

"&amp;"

document member of the same patent family

Date of the actual completion of the international search

19 FEBRUARY 1995

Date of mailing of the international search report

03 APR 1995

Name and mailing address of the ISA/US  
Commissioner of Patents and Trademarks  
Box PCT  
Washington, D.C. 20231

Facsimile No. (703) 305-3230

Authorized officer

PHILLIP GAMBEL

Telephone No. (703) 308-0196

# INTERNATIONAL SEARCH REPORT

International application No.  
PCT/US94/14767

## C (Continuation). DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
Y	LEUKEMIA, VOLUME 4, ISSUED 1990, LAW ET AL., "ANALYSIS OF EXPRESSION AND FUNCTION OF CD40 ON NORMAL AND LEUKEMIC HUMAN B CELL PRECURSORS", PAGES 732-738 , SEE ENTIRE DOCUMENT.	1-31

# INTERNATIONAL SEARCH REPORT

International application No.  
PCT/US94/14767

## A. CLASSIFICATION OF SUBJECT MATTER:

IPC (6):

A61K 38/00, 39/00, 39/395; C07K 14/00, 14/435, 14/705, 16/00, 16/18, 16/46

## A. CLASSIFICATION OF SUBJECT MATTER:

US CL :

424/130.1, 133.1, 134.1, 136.1, 138.1, 141.1, 143.1, 144.1,; 435/252.3, 320.1; 514/2, 8; 530/350, 351, 388. 22, 380.73